The short version of LC-MS fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-18. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
== Regulatory status == PRP is not regulated by the FDA because, like certain other human tissue and blood products, it is exempted from the traditional regulatory pathways; any use of PRP in a clinical setting is therefore considered "off label". The medical devices used to prepare PRP, however, are subject to FDA clearance.
== Patents == U.S. patent 2,163,754 was issued on June 27, 1939 – Ticket dispensing machine. U.S. patent D132,182 was issued on April 28, 1942 – Design for air conditioning unit. U.S. patent 2,336,735 was issued on December 14, 1943 – Removable cooling units for compartments. U.S. patent 2,337,164 was issued on December 21, 1943 – Means for automatically stopping and starting gas engines. U.S. patent 2,376,968 was issued on May 29, 1945 – Two-cycle gas engine. U.S. patent 2,417,253 was issued on March 11, 1947 – Two-cycle gas engine. U.S. patent 2,475,841 was issued on July 12, 1949 – Automatic refrigeration system for long-haul trucks. U.S. patent 2,475,842 was issued on July 12, 1949 – Starter generator. U.S. patent 2,475,843 was issued on July 12, 1949 – Means operated by a starter generator for cooling a gas engine. U.S. patent 2,477,377 was issued on July 26, 1949 – Means for thermostatically operating gas engines. U.S. patent 2,504,841 was issued on April 18, 1950 – Rotary compressor. U.S. patent 2,509,099 was issued on May 23, 1950 – System for controlling operation of refrigeration units. U.S. patent D159,209 was issued on July 4, 1950 – Design for air conditioning unit. U.S. patent 2,523,273 was issued on September 26, 1950 – Engine actuated ventilating system. U.S. patent 2,526,874 was issued on October 24, 1950 – Apparatus for heating or cooling atmosphere within an enclosure. U.S. patent 2,535,682 was issued on December 26, 1950 – Prefabricated refrigerator construction. U.S. patent 2,581,956 was issued on January 8, 1952 – Refrigeration control device. U.S.
=== 1964–1988: Early work and rise to prominence === Freeman worked as a dancer at the 1964 World's Fair and was a member of the Opera Ring musical theater group in San Francisco. He acted in a touring company version of The Royal Hunt of the Sun, and also appeared as an extra in Sidney Lumet's 1965 drama film The Pawnbroker starring Rod Steiger. Between acting and dancing jobs, Freeman realized that acting was where his heart lay. "After The Royal Hunt of the Sun, my acting career just took off", he later recalled. Freeman made his Off-Broadway debut in 1967, opposite Viveca Lindfors in The Niggerlovers, a show about the Freedom Riders during the American Civil Rights Movement, before debuting on Broadway in 1968's all-black version of Hello, Dolly! that also starred Pearl Bailey and Cab Calloway. In 1969, Freeman also performed on stage in The Dozens. Beginning in 1971, Freeman starred in the PBS children's television show The Electric Company, which gave him financial stability and recognition among American audiences. His work on the show was tiring, so he quit in 1975. Television producer Joan Ganz Cooney said that Freeman loathed appearing in The Electric Company, saying "it was a very unhappy period in his life". Freeman later acknowledged that he does not think about the show, but he was grateful to have been a part of it. His first credited appearance in a feature film was in 1971's Who Says I Can't Ride a Rainbow!, a family drama starring Jack Klugman. Also that year, Freeman performed in a theater production of Purlie.
Sources: en.wikipedia.org
=== COVID-19 therapy === In a phase III study on the treatment of severe courses of COVID-19, sabizabulin reduced mortality by 55% according to the manufacturer. Because of the high efficacy, the test phase was stopped prematurely so that the drug no longer had to be withheld from the placebo control group.
=== Gonadectomy === While it was often recommended that women with CAIS eventually undergo gonadectomy to mitigate cancer risk, there are differing opinions regarding the necessity and timing of gonadectomy. The risk of malignant germ cell tumors with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. However, only three cases of malignant germ cell tumors in prepubescent girls with CAIS have been reported in the last 100 years. The youngest of these children was 14 years old. Individuals with CAIS naturally go through puberty via the aromatization of testosterone into estrogens. Therefore, removal of the gonads will result in an individual requiring hormone replacement therapy. Gonadectomy is generally not recommended before puberty to allow for puberty to occur spontaneously. Some individuals with CAIS may choose to go on testosterone HRT rather than estrogen. Research suggests that testosterone is at least as beneficial as estrogen replacement therapy and possibly improves outcomes in certain areas of well-being. If gonadectomy is performed early, then puberty must be artificially induced using gradually increasing doses of estrogen. If gonadectomy is performed late, then puberty will occur on its own, due to the aromatization of testosterone into estrogen.
Molecular nanotechnology is a speculative subfield of nanotechnology regarding the possibility of engineering molecular assemblers, biological machines which could re-order matter at a molecular or atomic scale. Nanomedicine would make use of these nanorobots, introduced into the body, to repair or detect damages and infections, but these are considered to be far beyond current capabilities.
Sources: en.wikipedia.org
At the time, low-potency creatine supplements were available in Britain, but creatine supplements designed for strength enhancement were not commercially available until 1993 when the company Experimental and Applied Sciences (EAS) introduced the compound to the sports nutrition market under the name Phosphagen. In 1996, researchers found that carbohydrate consumption augments the effects of creatine supplementation on skeletal muscle creatine accumulation.
Pudzianowski is liberal with his diet and is often seen eating chocolate, ice cream or burgers. On one of the World Strongman events shown on TV, and an interview for MTV, when asked about his diet he said: "I eat everything. I do not follow any particular diet. I eat anything I want, anytime I want".
P2Y purinoceptor 11 is a protein that in humans is encoded by the P2RY11 gene. The product of this gene, P2Y11, belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is coupled to the stimulation of the phosphoinositide and adenylyl cyclase pathways and behaves as a selective purinoceptor. Naturally occurring read-through transcripts, resulting from intergenic splicing between this gene and an immediately upstream gene (PPAN, encoding peter pan homolog), have been found. The PPAN-P2RY11 read-through mRNA is ubiquitously expressed and encodes a fusion protein that shares identity with each individual gene product.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.